Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4

Proteomics

Volumn 8, Issue 16, 2008, Pages 3360-3370

  Matsumoto, Kunio ^a   Nakamura, Takahiro ^a   Sakai, Katsuya ^b   Nakamura, Toshikazu ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

HGF; Met; Metastasis; NK4; Tumor angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; GEMCITABINE; NK4 PROTEIN; PROTEIN DERIVATIVE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SERINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CANCER INVASION; CANCER THERAPY; CELL INTERACTION; CELL ISOLATION; COLON CANCER; COLON CARCINOMA; EXPERIMENTAL MODEL; EXPERIMENTAL NEOPLASM; GALLBLADDER CANCER; GLIOBLASTOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; METASTASIS; MUTATION; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR GROWTH;

HEPATOCYTE GROWTH FACTOR; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 50449087162     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800156     Document Type: Review

References (91)

1. Birchmeier, C., Birchmeier, W., Gherardi, E., Vande Woude, G. F., Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4, 915-925.
2. Jiang, W. G., Martin, T. A., Parr, C., Davies, G. et al., Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol. Hematol. 2005, 53, 35-69.
3. Matsumoto, K., Nakamura, T., Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J. Cancer 2006, 119, 477-483.
4. Nakamura, T., Nawa, K., Ichihara, A., Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun. 1984, 122, 1450-1459.
5. Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T. et al., Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342, 440-443.
6. Miyazawa, K., Tsubouchi, H., Naka, D., Takahashi, K. et al., Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem. Biophys. Res. Commun. 1989, 163, 967-973.
7. Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M. I. et al., Identification of hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251, 802-804.
8. Naldini, L., Vigna, E., Narsimhan, R. P., Gaudino, G. et al., Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991, 6, 501-504.
9. Birchmeier, C., Gherardi, E., Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 1998, 8, 404-411.
10. Matsumoto, K., Nakamura, T., Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem. Biophys. Res. Commun. 1997, 239, 639-644.
11. Bussolino, F., Di Renzo, M. F., Ziche, M., Bochietto, E. et al., Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 1992, 119, 629-641.
12. Kajiya, K., Hirakawa, S., Ma, B., Drinnenberg, I., Detmar, M., Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 2005, 24, 2885-2895.
13. Jiang, W. G., Davies, G., Martin, T. A., Parr, C. et al., The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int. J. Mol. Med. 2005, 16, 723-728.
14. Cao, R., Björndahl, M. A., Gallego, M. I., Chen, S. et al., Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood 2006, 107, 3531-3536.
15. Date, K., Matsumoto, K., Shimura, H., Tanaka, M., Nakamura, T., HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett. 1997, 420, 1-6.
16. Matsumoto, K., Nakamura, T., NK4 (HGF-antagonist and angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 2003, 94, 321-327.
17. Matsumoto, K., Nakamura, T., Mechanisms and significance of bifunctional NK4 in Cancer Treatment. Biochem. Biophys. Res. Commun. 2005, 333, 316-327.
18. Mueller, M. M., Fusenig, N. E., Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4, 839-849.
19. Bhowmick, N. A., Moses, H. L., Tumor-stroma interactions. Curr. Opin. Genet. Dev. 2005, 15, 97-101.
20. Olumi, A. F., Grossfeld, G. D., Hayward, S. W., Carroll, P. R. et al., Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59, 5002-5011.
21. Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E. et al., TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303, 848-851.
22. Matsumoto, K., Horikoshi, M., Rikimaru, K., Enomoto, S., A study of an in vitro model for invasion of oral squamous cell carcinoma. J. Oral Pathol. Med. 1989, 18, 498-501.
23. Matsumoto, K., Matsumoto, K., Nakamura, T., Kramer, R. H., Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J. Biol. Chem. 1994, 269, 31807-31813.
24. Matsumoto, K., Date, K., Shimura, H., Nakamura, T., Acquisition of invasive phenotype in gallbladder cancer cells via mutual interaction of stromal fibroblasts and cancer cells as mediated by hepatocyte growth factor. Cancer Sci. 1996, 87, 702-170.
25. Nakamura, T., Matsumoto, K., Kiritoshi, A., Tano, Y., Nakamura, T., Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: In vitro analysis of tumor-stromal interactions. Cancer Res. 1997, 57, 3305-3313.
26. Matsumoto-Taniura, N., Matsumoto, K., Nakamura, T., Prostaglandin production in mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts. Br. J. Cancer 1999, 81, 194-202.
27. Jiang, W. G., Hiscox, S., Matsumoto, K., Nakamura, T., Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit. Rev. Oncol. Hematol. 1999, 29, 209-248.
28. Tokunou, M., Niki, T., Eguchi, K., Iba, S. et al., c-MET expression in myofibroblasts: Role in autocrine activation and prognostic significance in lung adenocarcinoma. Am. J. Pathol. 2001, 158, 1451-1463.
29. Seslar, S. P., Nakamura, T., Byers, S. W., Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. Cancer Res. 1993, 53, 1233-1238.
30. Hasina, R., Matsumoto, K., Matsumoto-Taniura, N., Kato, I. et al., Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line. Br. J. Cancer 1999, 80, 1708-1717.
31. Apte, R. N., Voronov, E., Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Semin. Cancer Biol. 2002, 12, 277-290.
32. Michelson, S., Leith, J. T., Host response in tumor growth and progression. Invasion Metastasis 1996, 16, 235-246.
33. Ostman, A., PDGF receptors - mediators of autocrine tumor growth and regulatoirs of tumor vasculature and stroma. Cytokine Growth Factor Rev. 2004, 15, 275-286.
34. Wells, A., EGF receptor. Int. J. Biochem. Cell Biol. 1999, 31, 637-643.
35. Masferrer, J., Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J. 2001, 7, S144-S150.
36. Machide, M., Hashigasako, A., Matsumoto, K., Nakamura, T., Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/HGF receptor and LAR protein tyrosine phosphatase. J. Biol. Chem. 2006, 281, 8765-8772.
37. Gandino, L., Longati, P., Medico, E., Prat, M., Comoglio, P. M., Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J. Biol. Chem. 1994, 269, 1815-1820.
38. Hashigasako, A., Machide, M., Nakamura, T., Matsumoto, K., Nakamura, T., Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor. J. Biol. Chem. 2004, 279, 26445-26452.
39. Conacci-Sorrell, M., Zhurinsky, J., Ben-Ze'ev, A., The cadherin-catenin adhesion system in signaling and cancer. J. Clin. Invest. 2002, 109, 987-991.
40. Lee, J. H., Han, S. U., Cho, H., Jennings, B. et al., A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000, 19, 4947-4953.
41. Peschard, P., Fournier, T. M., Lamorte, L., Naujokas, M. A. et al., Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 2001, 8, 995-1004.
42. Kong-Beltran, M., Seshagiri, S., Zha, J., Zhu, W. et al., Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006, 66, 283-289.
43. Christensen, J. G., Schreck, R., Burrows, J., Kuruganti, P. et al., A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003, 63, 7345-7355.
44. Sattler, M., Pride, Y. B., Ma, P., Gramlich, J. L. et al., A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003, 63, 5462-5469.
45. Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y. et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316, 1039-1043.
46. Jiang, W. G., Grimshaw, D., Lane, J., Martin, T. A. et al., A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-METand reduces migration and invasiveness of breast cancer cells. Clin. Cancer Res. 2001, 7, 2555-2562.
47. Abounader, R., Lal, B., Luddy, C., Koe, G., et al., In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 2002, 16, 108-110.
48. Jiang, W. G., Grimshaw, D., Martin, T. A., Davies, G. et al., Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET. Clin. Cancer Res. 2003, 9, 4274-4281.
49. Herynk, M. H., Stoeltzing, O., Reinmuth, N., Parikh, N. U. et al., Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res. 2003, 63, 2990-2996.
50. Shinomiya, N., Gao, C. F., Xie, Q., Gustafson, M. et al., RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res. 2004, 64, 7962-7970.
51. Cao, B., Su, Y., Oskarsson, M., Zhao, P. et al., Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA 2001, 98, 7443-7448.
52. Michieli, P., Mazzone, M., Basilico, C., Cavassa, S. et al., Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004, 6, 61-73.
53. Mazzone, M., Basilico, C., Cavassa, S., Pennacchietti, S. et al., An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J. Clin. Invest. 2004, 114, 1418-1432.
54. Cioce, V., Csaky, K. G., Chan, A. M. L., Bottaro, D. P. et al., Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity, J. Biol. Chem. 1996, 271, 13110-13115.
55. Schwall, R. H., Chang, L. Y., Godowski, P. J., Kahn, D. W. et al., Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2, J. Cell Biol. 1996, 133, 709-718.
56. Silvagno, F., Follenzi, A., Arese, M., Prat, M. et al., In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis, Arterioscler. Thromb. Vasc. Biol. 1995, 15, 1857-1865.
57. Maehara, N., Matsumoto, K., Kuba, K., Mizumoto, K. et al., NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br. J. Cancer 2001, 84, 864-873.
58. Kuba, K., Matsumoto, K., Date, K., Shimura, H. et al., HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. 2000, 60, 6737-6743.
59. Kuba, K., Matsumoto, K., Ohnishi, K., Shiratsuchi, T. et al., Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells. Biochem. Biophys. Res. Commun. 2000, 279, 846-852.
60. Merkulova-Rainon, T., England, P., Ding, S., Demerens, C., Tobelem, G., The N-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor, J. Biol. Chem. 2003, 278, 37400-37408.
61. Xin, L., Xu, R., Zhang, Q., Li, T., Gan, R., Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis, Biochem. Biophys. Res. Commun. 2000, 277, 186-190.
62. Wen, J., Matsumoto, K., Taniura, N., Tomioka, D., Nakamura, T., Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther. 2004, 11, 419-430.
63. Tomioka, D., Maehara, N., Kuba, K., Mizumoto, K. et al., Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res. 2001, 61, 7518-7524.
64. Martin, T. A., Parr, C., Davies, G., Watkins, G. et al., Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, the HGF/SF antagonist. Carcinogenesis 2003, 24, 1317-1323.
65. Maemondo, M., Narumi, K., Saijo, Y., Usui, K. et al., Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF-antagonist NK4 for cancer therapy. Mol. Ther. 2002, 5, 177-185.
66. Kikuchi, T., Maemondo, M., Narumi, K., Matsumoto, K. et al., Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naïve dendritic cells. Blood 2002, 100, 3950-3959.
67. Wen, J., Matsumoto, K., Taniura, N., Tomioka, D., Nakamura, T., Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice. Biochem. Biophys. Res. Commun. 2007, 358, 117-123.
68. Kubota, T., Fujiwara, H., Amaike, H., Takashima, K. et al., Reduced HGF expression in subcutaneous C T26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects. Cancer Sci. 2004, 95, 321-327.
69. Jie, J. Z., Wang, J. W., Qu, J. G., Hung, T., Suppression of human colon tumor growth by adenoviral vector-mediated NK4 expression in an athymic mouse model. World J. Gastroenterol. 2007, 13, 1938-1946.
70. Yoshimura, M., Fujiwara, H., Kubota, T., Amaike, H. et al., Possible inhibition of cancer cell adhesion to the extracellular matrix in NK4-induced suppression of peritoneal implantation. Anticancer Res. 2005, 25, 3847-3854.
71. Kanehira, M., Xin, H., Hoshino, K., Maemondo, M. et al., Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther. 2007, 14, 894-903.
72. Date, K., Matsumoto, K., Kuba, K., Shimura, H. et al., Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998, 17, 3045-3054.
73. Tanaka, T., Shimura, H., Sasaki, T., Narumi, K. et al., Gallbladder cancer treatment using adenovirus expressing the HGF/NK4 gene in a peritoneal implantation model. Cancer Gene Ther. 2004, 11, 431-440.
74. Hirao, S., Yamada, Y., Koyama, F., Fujimoto, H. et al., Tumor suppression effect using NK4, a molecule acting as an antagonist of HGF, on human gastric carcinomas. Cancer Gene Ther. 2002, 9, 700-707.
75. Heideman, D. A. M., van Beusechem, A. W., Bloemena, E., Snijders, P. J. F. et al., Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4. J. Cancer Med. 2004, 6, 317-327.
76. Ueda, K., Iwahashi, M., Matsuura, I., Nakamori, M. et al., Adenoviral-mediated Gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice. Eur. J. Cancer 2004, 40, 2135-2142.
77. Fujiwara, H., Kubota, T., Amaike, H., Inada, S. et al., Suppression of peritoneal implantation of gastric cancer cells by adenovirus vector-mediated NK4 expression. Cancer Gene Ther. 2005, 12, 206-216.
78. Namiki, Y., Namiki, T., Yoshida, H., Date, M. et al., Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD 1839, Iressatrade mark) for disseminated peritoneal scirrhous gastric cancer. Int. J. Cancer 2006, 118, 1545-1555.
79. Brockmann, M. A., Papadimitriou, A., Brandt, M., Fillbrandt, R. et al., Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin. Cancer Res. 2003, 9, 4578-4585.
80. Heideman, D. A., Overmeer, R. M., van Beusechem, V. W., Lamers, W. H. et al., Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy. Cancer Gene Ther. 2005, 12, 954-629.
81. Son, G., Hirano, T., Seki, E., Iimuro, Y. et al., Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. J. Hepatol. 2006, 45, 688-695.
82. Kushibiki, T., Matsumoto, K., Nakamura, T., Tabata, Y., Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin. Gene Ther. 2004, 11, 1205-1214.
83. Maemondo, M., Saijo, Y., Narumi, K., Kikuchi, T. et al., Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer. Cancer Res. 2004, 64, 4611-4620.
84. Du, W., Hattori, Y., Yamada, T., Matsumoto, K. et al., NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells in vivo; molecular targeting of angiogenic growth factor. Blood 2007, 109, 3042-3049.
85. Saga, Y., Mizukami, H., Suzuki, M., Urabe, M. et al., Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. Gene Ther. 2001, 8, 1450-1455.
86. Saimura, M., Nagai, E., Mizumoto, K., Maehara, N. et al., Intraperitoneal injection of adenovirus-mediated NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nude mice. Cancer Gene Ther. 2002, 9, 799-806.
87. Maehara, N., Nagai, E., Mizumoto, K., Sato, N. et al., Gene transduction of NK4, HGF antagonist, inhibits in vitro invasion and in vivo growth of human pancreatic cancer. Clin. Exp. Metastasis 2002, 19, 417-426.
88. Saimura, M., Nagai, E., Mizumoto, K., Maehara, N. et al., Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clin. Cancer Res. 2002, 8, 3243-3249.
89. Manabe, T., Mizumoto, K., Nagai, E., Matsumoto, K. et al., Cell-based protein delivery system for the inhibition of the growth of pancreatic cancer: NK4 gene-transduced oral mucosal epithelial cell sheet. Clin. Cancer Res. 2003, 9, 3158-3166.
90. Ogura, Y., Mizumoto, K., Nagai, E., Murakami, M. et al., Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Ther. 2006, 13, 520-529.
91. Davies, G., Mason, M. D., Martin, T. A., Parr, C. et al., The HGF/SF antagonist NK4, reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int. J. Cancer 2003, 106, 348-354.